From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary
Revista de Saúde Pública
Vol 52 (2018)
What is the importance of vaccine hesitancy in the drop of vaccination coverage in Brazil?
Ana Paula Sayuri Sato
The successful Programa Nacional de Imunizações do Brasil (Brazilian National Immunization Program) has been experiencing a major challenge with regard to vaccination coverage for children, which has been dropping. Several aspects are related, but certainly vaccine hesitancy has been strengthening itself as one of the main concerns of Brazilian public administrators and researchers. Vaccine hesitancy is the delay in acceptance or refusal despite having the recommended vaccines available in health services, being a phenomenon that varies over time, over location and over types of vaccines. Hesitant individuals are between the two poles of total acceptance and refusal of vaccination. Vaccine hesitancy is nothing new in European and North-American countries, and even in Brazil, it has been studied even if under another name. The drop of vaccination coverage observed from 2016 on reiterates the relevance of the theme, which must be better understood through scientific research.
Revista Latinoamericana de Infectología Pediátrica
2018; 31 (3)
Dengue surveillance in children who received CYD tetravalent dengue vaccine during their second year of life while participating in a clinical trial in a southern state of Mexico
JL Arredondo-García, FI Rodríguez Melo, S Canche…
Dengue is a systemic viral infection transmitted to humans by mosquitoes and is a public health challenge due to its rapid global expansion and lack of specific therapeutic agents. To date (January 2018), the CYD-TDV vaccine has been granted licensure in 19 countries. The World Health Organization global strategy for dengue prevention and control 2012-2020 has, as a global goal, the reduction of the burden of disease. One of the technical elements of this strategy is the implementation of a dengue vaccine. This is an epidemiological descriptive study of 248 subjects with retrospective and passive surveillance for 2 years; from this cohort, 162 subjects, ages 4 years 8 months to 5 years 9 months, underwent active surveillance. Eligible participants were children who participated in the previous randomized phase III trial conducted in Merida, Yucatan, Mexico. All the subjects who completed the previous trial were included for retrospective/passive surveillance; the subjects who underwent active surveillance (n = 162 subjects) were identified during a three-month enrollment period. Blood draws and phone calls (study procedures) were performed under the applicable local and international regulations. None of the 248 participants followed for passive surveillance had a reported confirmed dengue case. Forty-one cases of suspected vector-transmitted disease without virological or serological confirmation were detected. The result of this study provides support for the safety of the vaccine in this age group. Further follow-ups in similar populations should be done in order to obtain more information.